Barclays’s Scinai Immunotherapeutics SCNI Stock Holding History

Barclays’s Portfolio SCNI Stock Details SCNI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1	Closed	–	–	4670
2021 Q3	$0	Hold	1	–	–	﹤0.01%	4974
2021 Q2	$0	Hold	1	–	–	﹤0.01%	5053
2021 Q1	$0	Buy	+1	New	+$437	﹤0.01%	5126

Other funds holding SCNI

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

TPWA

TRUE Private Wealth Advisors Salem, Oregon $1.16B AUM 36.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ECM

ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Credit Agricole Montrouge Cedex, France $38.1B AUM

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Barclays's SCNI Position: Q4 2021 in Review

Barclays sold out of Scinai Immunotherapeutics (SCNI) in Q4 2021, closing a stake of 1 share.

Barclays first reported a position in SCNI in Q1 2021 and held it in 3 quarters. The position peaked at $0 in Q3 2021. 14 funds tracked by Wall St. Rank hold SCNI as of Q4 2021.

Barclays reported no remaining Scinai Immunotherapeutics position as of Q4 2021 after selling out during the quarter.
Barclays sold 1 Scinai Immunotherapeutics share in Q4 2021.
Barclays first reported a position in Scinai Immunotherapeutics in Q1 2021 and held it in 3 quarters.
Barclays's Scinai Immunotherapeutics position peaked at $0 in Q3 2021.
14 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q4 2021.

Based on Barclays's 13F filing for Q4 2021, filed 14 Feb 2022.